UNLABELLED: High-dose (28-30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve survival and is associated with increased rates of serious adverse events. The mechanism for the latter undesired effect remains unclear. High-dose UDCA could result in the production of hepatotoxic bile acids, such as lithocholic acid (LCA), because of limited small bowel absorption of UDCA and conversion of UDCA by bacteria in the colon. We determined the serum bile acid composition in 56 patients with PSC previously enrolled in a randomized, double-blind controlled trial of high-dose UDCA versus placebo. Samples for analysis were obtained at the baseline and at the end of treatment. The mean changes in the UDCA level (16.86 versus 0.05 micromol/L) and total bile acid level (17.21 versus -0.55 micromol/L) were significantly higher in the UDCA group (n = 29) versus the placebo group (n = 27) when pretreatment levels were compared (P < 0.0001). LCA was also markedly increased (0.22 versus 0.01 micromol/L) in the UDCA group compared to the placebo group (P = 0.001). No significant changes were detected for cholic acid, deoxycholic acid, or chenodeoxycholic acid. Patients (n = 9) in the UDCA group who reached clinical endpoints of disease progression (the development of cirrhosis, varices, liver transplantation, or death) tended to have greater increases in their posttreatment total bile acid levels (34.99 versus 9.21 micromol/L, P < 0.08) in comparison with those who did not. CONCLUSION: High-dose UDCA treatment in PSC patients results in marked UDCA enrichment and significant expansion of the total serum bile acid pool, including LCA.
RCT Entities:
UNLABELLED: High-dose (28-30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve survival and is associated with increased rates of serious adverse events. The mechanism for the latter undesired effect remains unclear. High-dose UDCA could result in the production of hepatotoxicbile acids, such as lithocholic acid (LCA), because of limited small bowel absorption of UDCA and conversion of UDCA by bacteria in the colon. We determined the serum bile acid composition in 56 patients with PSC previously enrolled in a randomized, double-blind controlled trial of high-dose UDCA versus placebo. Samples for analysis were obtained at the baseline and at the end of treatment. The mean changes in the UDCA level (16.86 versus 0.05 micromol/L) and total bile acid level (17.21 versus -0.55 micromol/L) were significantly higher in the UDCA group (n = 29) versus the placebo group (n = 27) when pretreatment levels were compared (P < 0.0001). LCA was also markedly increased (0.22 versus 0.01 micromol/L) in the UDCA group compared to the placebo group (P = 0.001). No significant changes were detected for cholic acid, deoxycholic acid, or chenodeoxycholic acid. Patients (n = 9) in the UDCA group who reached clinical endpoints of disease progression (the development of cirrhosis, varices, liver transplantation, or death) tended to have greater increases in their posttreatment total bile acid levels (34.99 versus 9.21 micromol/L, P < 0.08) in comparison with those who did not. CONCLUSION: High-dose UDCA treatment in PSCpatients results in marked UDCA enrichment and significant expansion of the total serum bile acid pool, including LCA.
Authors: Peter Fickert; Andrea Fuchsbichler; Hanns-Ulrich Marschall; Martin Wagner; Gernot Zollner; Robert Krause; Kurt Zatloukal; Hartmut Jaeschke; Helmut Denk; Michael Trauner Journal: Am J Pathol Date: 2006-02 Impact factor: 4.307
Authors: Rolf Olsson; Kirsten M Boberg; Ove Schaffalitsky de Muckadell; Stefan Lindgren; Rolf Hultcrantz; Geir Folvik; Helge Bell; Magnhild Gangsøy-Kristiansen; Jon Matre; Andreas Rydning; Ola Wikman; Ake Danielsson; Hanna Sandberg-Gertzén; Kjell-Arne Ung; Anders Eriksson; Lars Lööf; Hanne Prytz; Hanns-Ulrich Marschall; Ulrika Broomé Journal: Gastroenterology Date: 2005-11 Impact factor: 22.682
Authors: B Combes; R L Carithers; W C Maddrey; S Munoz; G Garcia-Tsao; G F Bonner; J L Boyer; V A Luketic; M L Shiffman; M G Peters; H White; R K Zetterman; R Risser; S S Rossi; A F Hofmann Journal: Hepatology Date: 1999-06 Impact factor: 17.425
Authors: Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders Journal: Hepatology Date: 2009-09 Impact factor: 17.425
Authors: Susan N Cullen; Christian Rust; Kenneth Fleming; Cathryn Edwards; Ulrich Beuers; Roger W Chapman Journal: J Hepatol Date: 2008-02-14 Impact factor: 25.083
Authors: M H Imam; E Sinakos; A A Gossard; K V Kowdley; V A C Luketic; M Edwyn Harrison; T McCashland; A S Befeler; D Harnois; R Jorgensen; J Petz; J Keach; A C DeCook; F Enders; K D Lindor Journal: Aliment Pharmacol Ther Date: 2011-09-29 Impact factor: 8.171
Authors: J Torres; X Bao; A Goel; J-F Colombel; J Pekow; B Jabri; K M Williams; A Castillo; J A Odin; K Meckel; F Fasihuddin; I Peter; S Itzkowitz; J Hu Journal: Aliment Pharmacol Ther Date: 2016-02-09 Impact factor: 8.171
Authors: Benjamin L Woolbright; Feng Li; Yuchao Xie; Anwar Farhood; Peter Fickert; Michael Trauner; Hartmut Jaeschke Journal: Toxicol Lett Date: 2014-04-15 Impact factor: 4.372